Conference Day One
For full session details, access the 2025 Full Event Guide here!
7:30 am Light Breakfast & Check-In
8:50 am Chair’s Opening Remarks
Enhancing Mass Spectrometry Through Optimized DIA & TMT Workflows to Balance Speed & Sensitivity for Reliable Workflows
9:00 am Optimizing Data Independent Acquisition for Comprehensive Target Discovery & Occupancy Assays with Higher Reproducibility
Synopsis
- Switching from a TMT focused approach to DIA for more reliable data acquisition
- Ensuring comprehensive coverage of the screening pool for covalent drug discovery using DIA approaches
- Enabling higher throughout DIA-based target occupancy assays to advance covalent drug development
9:30 am High-Throughput & Accurate Multiplexed Approach for Overcoming Bottlenecks in Large-Scale Proteomics
Synopsis
- Deeply profiled over 300 tissue samples with TMT-based proteomics, completing sample preparation in under two weeks
- Established high-throughput analysis with minimal sample-to-sample variability through an in-house developed robust, automated multiplexed proteomics platform
- Achieved high quantification accuracy by utilizing ion data and a specific experimental design for precise protein quantification across numerous samples and acquisition runs
10:00 am Assays & Strategies to Interrogate the Proteome for Drug Discovery
Synopsis
- How proteomics can create value in all stages of preclinical drug discovery
- ProteomeScout™ HT is a fast and cost-effective assay for phenotypic characterization of compounds, to guide SAR and validate MOA
- SideScout™ is a label-free assay for target engagement and selectivity profiling in lysates and live cells
- Proteomic data products provide quick access to valuable information to drive decisions
10:15 am Morning Break & Speed Networking
Unveiling Protein-Protein Interactions: Advancing Protein Complex Studies Through Translational Proteomic for Informing Drug Development
11:15 am Decoding Protein Protein Interactions: Insights from Affinity Purification Mass Spectrometry and Convergent Network Analysis
Synopsis
- Elucidation of novel drug targets using network analysis and APMS
- The investigation of differential protein-protein interaction (PPI) networks in response to drugs
- Leveraging complementary MS based proteomics approaches to gain further insight into PPIs and network biology
11:45 am Harnessing Disruptive Technology in a Service Laboratory: Proteomics in the Astral Era
Synopsis
- Conversation about the impact of the Orbitrap Astral on routine and non-routine proteomics
- Discussion on the recent past, near- and long-term future of mass spectrometry-based proteomics
12:15 pm Lunch Break & Networking
Optimizing Proteomics Approaches for Covalent Drug Discovery: Addressing Specificity, Probe Development, & Metabolite Challenges
1:15 pm Advancing Histidine, Tyrosine and Lysine (HYK) Covalent Probes in Mass Spectrometry
Synopsis
- Using mass spectrometry to optimize probes for covalent targeting of HYK residues that can monitor novel pockets across the proteome
- Developing methods for robust high-throughput mass spec analysis of HYK probelabeled peptides
- Leveraging the HYKU platform to support covalent and non-covalent drug discovery programs
1:45 pm Harnessing Proteomics & Deep Learning Approaches to Enable Covalent Drug Discovery
Synopsis
- Systematic and proteome-wide druggability of proteins in the native setting is synergistically enabled by the combination of Covalency and Mass Spectrometry
- Deep Learning improves deconvolution of Mass Spectrometry-based Proteomics data and boosts the sequence coverage of Covalent Chemoproteomics
- Structural Mass Spectrometry combined with machine learning for improved prediction of ligandability of residues, protein structure, and topology
2:15 pm Covalent Drug Discovery by Chemoproteomics: Deconvolution of Phenotypic Screening Hits Through IMTAC Proteome-Wide, Live-Cell Screening
Synopsis
- Discussing the advantages of IMTAC proteome-wide, live-cell screening to further drug discovery efforts
- Identification of novel targets with the potential to overcome acquired chemotherapy resistance in high-grade serous ovarian cancer
2:45pm Afternoon Networking Break & Poster Session
Advancing Proteomic Approaches for the Discovery & Development of Improved Protein Degraders
3:45 pm Using Proteomics to Accelerate Drug Discovery in Targeted Protein Degradation
Synopsis
- Application of mass spectrometry-based proteomics in TPD development process, from target identification and validation to protein-protein interaction
- Proteomics strategies to dissect protein degradation mechanism
- Optimizing LC-MS/MS methods to maximize throughput and sensitivity while balancing quality and data confidence
- Streamlining data analysis to increase productivity and discovery of actionable drug targets
4:15 pm Leveraging Proteomics to Accelerate Target Identification for Molecular Glue Degraders
Synopsis
- Developing proteomics platform for molecular glue degraders
- Increasing Proteomics throughput using DIA approach to accelerate target identification
- Combining proteomics, structural biology, and proximity labelling techniques to efficiently validate and characterize novel targets.